Abilify Therapy for Reducing Comorbid Substance Abuse
Completed · Phase 4
Conditions studied: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
In brief
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: * Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) * Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale * Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.
Key facts
- Study ID
- NCT00208169
- Run by
- Creighton University
- People needed
- 30
- Starts
- 2005-03-01
- Expected to finish
- 2007-06-01
- Last updated by the study team
- 2007-08-24
Who can join
Age: 19 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Ages 19 - 65
- Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, or anxiety (panic disorder, generalized anxiety disorder, or post-traumatic stress disorder) as confirmed by Mini International Neuropsychiatric Interview (MINI) structured assessment
- Diagnosis of comorbid substance abuse/dependence as confirmed by the MINI structured assessment
- Ability to provide signed informed consent
- Stable general medical health
- Ability to attend outpatient research clinic.
You may not qualify if…
- Dangerous to self or others
- Pregnancy, or inability or unwillingness to use approved methods of birth control
- Inability or unwillingness to provide signed informed consent
- Inability to attend outpatient research clinic
- Medical conditions, which would preclude use of aripiprazole
- Absolute need for ongoing treatment with antipsychotic other than aripiprazole
- Medical instability defined as likelihood of needing to change prescription medication during the course of the study
- Patients with prior unsuccessful treatment with aripiprazole
- Patients with a psychiatric diagnosis of only antisocial personality disorder or only an eating disorder and comorbid substance abuse/dependence.
Where it is running
- Creighton University Psychiatry and Research Center — Omaha, Nebraska, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.